Market Overview

Recap: Reata Pharmaceuticals Q3 Earnings



Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 0.76% over the past year to ($1.31), which beat the estimate of ($1.98).

Revenue of $1,401,000 declined by 83.00% year over year, which beat the estimate of $1,270,000.


Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $257.96

Company's 52-week low was at $88.17

Price action over last quarter: Up 49.61%

Company Profile

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.


Related Articles (RETA)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at